Profile data is unavailable for this security.
About the company
Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.
- Revenue in HUF (TTM)798.94bn
- Net income in HUF187.88bn
- Incorporated1923
- Employees11.60k
- LocationRichter Gedeon Vegyeszeti Gyar NyrtGyomroi ut 19-21.BUDAPEST 1103HungaryHUN
- Phone+36 14314000
- Fax+36 12606650
- Websitehttps://www.gedeonrichter.com/hu-hu/
More ▼
Mergers & acquisitions
| Acquired company | RICHTER:BUD since announced | Transaction value |
|---|---|---|
| Richter-Helm Biologics GmbH & Co KG | 1.82% | 44.07m |
| Richter-Helm Biotec GmbH & Co. KG | 1.82% | 77.94m |
| Giskit MD BV | 11.08% | 33.59m |
Data delayed at least 15 minutes, as of Jul 17 2024 13:04 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Ltd | 508.78bn | -81.79bn | 1.71tn | 15.56k | -- | 5.07 | -- | 3.37 | -67.28 | -53.21 | 418.40 | 278.11 | 0.7004 | 1.81 | 4.28 | -- | -10.86 | 1.02 | -15.92 | 1.43 | 62.64 | 61.27 | -15.50 | 1.43 | 0.8447 | 1.19 | 0.1356 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| Avidity Biosciences Inc | 3.91bn | -82.27bn | 1.78tn | 253.00 | -- | 5.37 | -- | 455.83 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Apellis Pharmaceuticals Inc | 188.54bn | -150.12bn | 1.80tn | 702.00 | -- | 18.71 | -- | 9.53 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -38.72 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Rohto Pharmaceutical Co Ltd | 615.33bn | 70.28bn | 1.81tn | 7.26k | 25.01 | 3.13 | 19.93 | 2.95 | 135.21 | 135.21 | 1,183.75 | 1,079.72 | 0.8259 | 2.59 | 4.17 | 37,310,920.00 | 9.57 | 8.54 | 13.02 | 11.79 | 58.07 | 58.59 | 11.59 | 10.30 | 1.93 | -- | 0.0614 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 798.94bn | 187.88bn | 1.82tn | 11.60k | 9.59 | 1.51 | 7.60 | 2.28 | 1,020.54 | 1,020.53 | 4,335.98 | 6,494.05 | 0.5724 | 1.46 | 4.05 | 68,856,070.00 | 13.62 | 11.64 | 15.34 | 13.28 | 67.11 | 58.18 | 23.80 | 18.93 | 3.08 | -- | 0.0153 | 39.94 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.94 |
| Siegfried Holding AG | 511.91bn | 45.11bn | 1.83tn | 3.93k | 38.28 | 5.09 | 23.40 | 3.57 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| Laboratorios Farmaceuticos ROVI SA | 305.48bn | 54.05bn | 1.84tn | 2.11k | 33.29 | 8.65 | 29.33 | 6.01 | 2.60 | 2.60 | 14.74 | 10.03 | 0.9364 | 0.9838 | 5.34 | 369,045.00 | 16.56 | 18.90 | 22.75 | 25.58 | 58.01 | 59.82 | 17.69 | 20.13 | 0.771 | 812.80 | 0.135 | 34.37 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
| GlaxoSmithKline Pharmaceuticals Limited | 148.75bn | 25.41bn | 1.91tn | 3.21k | 74.98 | 24.88 | 67.05 | 12.81 | 34.82 | 34.82 | 203.88 | 104.93 | 1.00 | 2.71 | 16.67 | 10,755,860.00 | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 55.77 | 17.08 | 12.25 | 1.49 | 466.45 | 0.0104 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Hikma Pharmaceuticals Plc | 1.03tn | 68.37bn | 1.92tn | 8.97k | 28.06 | 2.41 | 13.90 | 1.85 | 0.6595 | 0.6595 | 9.97 | 7.67 | 0.6284 | 1.76 | 3.67 | 247,297.50 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| Krka d.d. Novo Mesto | 719.27bn | 126.97bn | 1.92tn | 11.80k | 14.26 | 2.04 | 11.50 | 2.67 | 10.48 | 10.48 | 59.36 | 73.17 | 0.6528 | 1.37 | 3.57 | 157,225.70 | 11.51 | 12.64 | 13.68 | 15.12 | 55.99 | 57.29 | 17.64 | 18.71 | 2.88 | 66.70 | 0.0056 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
| Organon & Co | 2.28tn | 376.68bn | 1.93tn | 10.00k | 5.10 | 110.92 | 4.15 | 0.8432 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| BridgeBio Pharma Inc | 78.64bn | -193.65bn | 1.97tn | 550.00 | -- | -- | -- | 25.04 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Financiere de Tubize SA | 0.00 | 34.57bn | 1.98tn | -- | 57.16 | 2.80 | 57.16 | -- | 1.98 | 1.98 | 0.00 | 40.36 | -- | -- | -- | -- | -- | 7.04 | -- | 7.24 | -- | -- | -- | 145.70 | -- | -- | 0.0422 | 20.94 | -- | -- | 3.50 | -20.93 | -- | 11.61 |
Data as of Jul 17 2024. Currency figures normalised to Richter Gedeon Vegyeszeti Gyar Nyrt's reporting currency: Hungarian Forint HUF
23.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 May 2024 | 10.99m | 5.90% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 5.84m | 3.14% |
| Orbis Investment Management Ltd.as of 31 Dec 2023 | 4.44m | 2.39% |
| Hermes Investment Management Ltd.as of 31 May 2024 | 4.25m | 2.28% |
| Seafarer Capital Partners LLCas of 31 Mar 2024 | 3.55m | 1.91% |
| Invesco Advisers, Inc.as of 31 May 2024 | 3.15m | 1.69% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.08m | 1.65% |
| Templeton Asset Management Ltd.as of 31 May 2024 | 2.95m | 1.58% |
| Schroder Investment Management Ltd.as of 31 May 2024 | 2.71m | 1.46% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 30 Apr 2024 | 2.27m | 1.22% |
More ▼
Data from 31 Dec 2023 - 31 May 2024Source: FactSet Research Systems Inc.
